Bank of America Initiates Momenta Pharmaceuticals At Underperform, $19 PO

June 28, 2011 7:25 AM | 7 seconds read |
Bank of America has initiated coverage on Momenta Pharmaceuticals MNTA with an Underperform rating and $19 price objective.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: Price TargetInitiationAnalyst RatingsBank of AmericaBiotechnologyHealth CareMomenta Pharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!